Abrysvo Vaccine: High Efficacy, RSV Protection for Adults & Mothers
Understanding the RSV Threat and the Promise of Abrysvo Respiratory Syncytial Virus (RSV) is a common virus, causing mild cold-like symptoms in most people. However, for older adults (60+) and infants, RSV can lead to severe lower respiratory tract infections (LRTIs), such as bronchiolitis and pneumonia, potentially requiring hospitalisation. The Abrysvo vaccine offers a significant advancement in preventing these serious RSV-related illnesses. Abrysvo Efficacy: Protecting Vulnerable Populations Extensive clinical trials demonstrated Abrysvo's impressive efficacy in reducing severe RSV....